News Breaks |
|
|
| March 5, 2013 |
| 11:30 EDT |  | RPRX, NS, ISRG | Options with increasing implied volatility: RPRX ISRG NS
|
|
|
News For RPRX;ISRG;NS From The Last 14 Days Check below for free stories on RPRX;ISRG;NS the last two weeks. |
|
|
| May 24, 2013 |
| 09:25 EDT |  | ISRG | On The Fly: Pre-market Movers
 Subscribe for More Information |
|
| 07:06 EDT |  | ISRG | Intuitive Surgical risk decreased by court decision, says Cantor
After Intuitive Surgical won the first of 26 cases alleging that patients' injuries or deaths were caused by the company's da Vinci robotic surgery product, Cantor thinks the decision indicates that the cases will not greatly damage the company's reputation. The firm reiterates a $575 price target and Buy rating on the stock. |
|
| 06:31 EDT | | ISRG | Intuitive Surgical verdict encouraging, legal risk remains, says Leerink
Subscribe for More Information |
|
| May 23, 2013 |
| 16:46 EDT |  | ISRG | Intuitive Surgical beats negligent training claims, Bloomberg says
Subscribe for More Information |
|
| 16:11 EDT | | ISRG | Intuitive Surgical rise 5% to $503.80 after jury reportedly rules in its favor
|
|
| 16:09 EDT | | ISRG | Intuitive Surgical wins trial, defeats claim of negligent traing, Bloomberg says
Subscribe for More Information |
|
| 15:31 EDT | | ISRG | Clerk says jury has reached verdict in Intuitive Surgical case, Bloomberg says
Subscribe for More Information |
|
| 15:31 EDT | | ISRG | Intuitive Surgical May weekly volatility increases to 80
Intuitive Surgical May weekly call option implied volatility is at 80, June is at 27, July and August is at 29; compared to its 26-week average 30 according to Track Data, suggesting large near term price movement on expectations a verdict from a Washington state jury. |
|
| May 22, 2013 |
| 20:03 EDT | | RPRX | Repros Therapeutics says FDA recommends Phase 2b trial of Proellex-V
Repros Therapeutics announced it has met with the FDA regarding the clinical development of Proellex-V, the vaginally administered product, in the treatment of uterine fibroids. The FDA recommended that a Phase 2b study should be conducted as a prelude to the Phase 3 program. The study will start in the latter half of this year and results are expected in mid-2014. The FDA also felt the studies should be one year in duration. The company was already planning large one year safety studies as part of its overall clinical package. NDA submission is expected in 2016. The outcome of the meeting does not materially affect the cost of the total development program, but it does reduce the cash requirements for Repros through 1Q14. |
|
| 11:02 EDT | | ISRG | Intuitive Surgical May weekly volatility elevated at 51
Intuitive Surgical May weekly call option implied volatility is at 51, June is at 26, July and August is at 29; compared to its 26-week average 30 according to Track Data, suggesting large near term price movement on expectations a Washington state jury will begin deliberations in Intuitive Surgical robotic case. |
| |
| 08:26 EDT | | ISRG | Jury to begin deliberations in Intuitive Surgical robotic case, Bloomberg says
In Washington state, jury deliberations are set to begin in the first case to go to trial of at least 26 lawsuits against Intuitive Surgical alleging injuries tied to its da Vinci robotic system, reports Bloomberg. Reference Link |
|
| 07:41 EDT | | ISRG | JPMorgan gets surgeon feedback after Intuitive Surgical notification
JPMorgan says none of the 25 urologic and gynecologic da Vinci surgeons it surveyed were planning to postpone procedures and send instruments back to Intuitive Surgical following the Urgent Medical Device Notification that the company sent out on May 8. JPMorgan said the surgeons, who use the -09 or -10 Monopolar Curved Scissors, said they will continue to use the instruments in a cautious manner. The firm keeps an Overweight rating on shares of Intuitive Surgical with a $625 price target. |
|
| May 20, 2013 |
| 15:42 EDT | | ISRG | Viking Global reports 5.1% passive stake in Intuitive Surgical
Subscribe for More Information |
|
| May 14, 2013 |
| 17:48 EDT | | ISRG | Lone Pine gives quarterly update on stakes
NEW STAKES: Valeant Pharmaceuticals (VRX), Virgin Media (VMED), Thermo Fisher Scientific (TMO), CME Group (CME), and Liberty Media (LMCA). INCREASED STAKES: Mead Johnson Nutrition (MJN), News Corp (NWSA), Intuitive Surgical (ISRG), Monsanto (MON), and Qualcomm (QCOM). DECREASED STAKES: Cognizant Technology Solutions (CTSH), Equinix (EQIX), Ralph Lauren (RL), Disney (DIS), and Oceaneering International (OII). LIQUIDATED STAKES: Facebook (FB), Crown Castle (CCI), Accretive Health (AH), Informatica (INFA), and NetEase (NTES). |
|
|
|
|
|
